Your browser doesn't support javascript.
loading
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
Zhang, Mingming; Wei, Guoqing; Zhou, Linghui; Zhou, Jincai; Chen, Siye; Zhang, Wei; Wang, Dongrui; Luo, Xueping; Cui, Jiazhen; Huang, Simao; Fu, Shan; Zhou, Xinkai; Tang, Yu; Ding, Xiaomin; Kuang, Jiao; He, Xiaowen Peter; Hu, Yongxian; Huang, He.
Afiliación
  • Zhang M; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Wei G; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Zhou L; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Zhou J; OriCell Therapeutics, Shanghai, China.
  • Chen S; OriCell Therapeutics, Shanghai, China.
  • Zhang W; OriCell Therapeutics, Shanghai, China.
  • Wang D; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Luo X; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Cui J; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Huang S; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Fu S; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Zhou X; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Tang Y; OriCell Therapeutics, Shanghai, China.
  • Ding X; OriCell Therapeutics, Shanghai, China.
  • Kuang J; OriCell Therapeutics, Shanghai, China.
  • He XP; OriCell Therapeutics, Shanghai, China.
  • Hu Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
  • Huang H; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Liangzhu Laboratory
Lancet Haematol ; 10(2): e107-e116, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36725117
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / COVID-19 / Anemia / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombocitopenia / COVID-19 / Anemia / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido